In vitro Antibacterial Activities of New Fluoroquinolones against Clinical Isolates of Haemophilus influenzae with Ciprofloxacin-Resistance-Associated Alterations in GyrA and ParC

Chemotherapy ◽  
2004 ◽  
Vol 50 (6) ◽  
pp. 265-275 ◽  
Author(s):  
Satoshi Yoshizumi ◽  
Yoshie Takahashi ◽  
Yoshinari Watanabe ◽  
Eiichi Okezaki ◽  
Yoshikazu Ishii ◽  
...  
Keyword(s):  
Haemophilus Influenzae ◽  
Antibacterial Activities ◽  
Clinical Isolates ◽  
Ciprofloxacin Resistance

scholarly journals Comparative In Vitro Activities of Nemonoxacin (TG-873870), a Novel Nonfluorinated Quinolone, and Other Quinolones against Clinical Isolates

2010 ◽  
Vol 54 (3) ◽  
pp. 1338-1342 ◽  
Author(s):  
Tsai-Ling Lauderdale ◽  
Yih-Ru Shiau ◽  
Jui-Fen Lai ◽  
Hua-Chien Chen ◽  
Chi-Hsin R. King
Keyword(s):  
Staphylococcus Aureus ◽  
Streptococcus Pneumoniae ◽  
Neisseria Gonorrhoeae ◽  
Haemophilus Influenzae ◽  
Antibacterial Activities ◽  
Clinical Isolates ◽  
Methicillin Resistant ◽  
Better Than

ABSTRACT The in vitro antibacterial activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, against 770 clinical isolates were investigated. Nemonoxacin (tested as its malate salt, TG-875649) showed better in vitro activity than ciprofloxacin and levofloxacin against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenzae. The in vitro activity of TG-875649 was also comparable to or better than that of moxifloxacin against these pathogens, which included ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus and levofloxacin-resistant Streptococcus pneumoniae.

scholarly journals In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii-calcoaceticus Complex Isolates Collected Globally in 2016 and 2017

2020 ◽  
Vol 64 (4) ◽  
Author(s):  
Sarah M. McLeod ◽  
Samir H. Moussa ◽  
Meredith A. Hackel ◽  
Alita A. Miller
Keyword(s):  
Acinetobacter Baumannii ◽  
Antibacterial Activities ◽  
Multidrug Resistant ◽  
Clinical Isolates ◽  
Single Amino Acid ◽  
Content Type ◽  
Level Of Activity ◽  
Severe Infections ◽  
Sources Of Infection

ABSTRACT Acinetobacter baumannii-calcoaceticus complex (ABC) organisms cause severe infections that are difficult to treat due to preexisting antibiotic resistance. Sulbactam-durlobactam (formerly sulbactam-ETX2514) (SUL-DUR) is a β-lactam–β-lactamase inhibitor combination antibiotic designed to treat serious infections caused by ABC organisms, including multidrug-resistant (MDR) strains. The in vitro antibacterial activities of SUL-DUR and comparator agents were determined by broth microdilution against 1,722 clinical isolates of ABC organisms collected in 2016 and 2017 from 31 countries across Asia/South Pacific, Europe, Latin America, the Middle East, and North America. Over 50% of these isolates were resistant to carbapenems. Against this collection of global isolates, SUL-DUR had a MIC50/MIC90 of 1/2 μg/ml compared to a MIC50/MIC90 of 8/64 μg/ml for sulbactam alone. This level of activity was found to be consistent across organisms, regions, sources of infection, and subsets of resistance phenotypes, including MDR and extensively drug-resistant isolates. The SUL-DUR activity was superior to those of the tested comparators, with only colistin having similar potency. Whole-genome sequencing of the 39 isolates (2.3%) with a SUL-DUR MIC of >4 μg/ml revealed that these strains encoded either the metallo-β-lactamase NDM-1, which durlobactam does not inhibit, or single amino acid substitutions near the active site of penicillin binding protein 3 (PBP3), the primary target of sulbactam. In summary, SUL-DUR demonstrated potent antibacterial activity against recent, geographically diverse clinical isolates of ABC organisms, including MDR isolates.

scholarly journals In Vitro Activities of the Ketolide HMR 3647 against Recent Gram-Positive Clinical Isolates and Haemophilus influenzae

1998 ◽  
Vol 42 (8) ◽  
pp. 2138-2140 ◽  
Author(s):  
Arthur L. Barry ◽  
Peter C. Fuchs ◽  
Steven D. Brown
Keyword(s):  
Haemophilus Influenzae ◽  
Clinical Isolates ◽  
Gram Positive

ABSTRACT The ketolide HMR 3647 (previously RU 66647) was evaluated against 2,563 recent clinical isolates of gram-positive pathogens and 200Haemophilus influenzae isolates. HMR 3647 was active against macrolide-resistant streptococci, including pneumococci, but was not active against macrolide- or lincosamide-resistant staphylococci. Against H. influenzae, the potency of HMR 3647 was similar to that of azithromycin.

scholarly journals In Vitro Antibacterial Activities of DQ-113, a Potent Quinolone, against Clinical Isolates

2002 ◽  
Vol 46 (3) ◽  
pp. 904-908 ◽  
Author(s):  
Mayumi Tanaka ◽  
Emi Yamazaki ◽  
Megumi Chiba ◽  
Kiyomi Yoshihara ◽  
Takaaki Akasaka ◽  
...  
Keyword(s):  
Streptococcus Pyogenes ◽  
Moraxella Catarrhalis ◽  
Antibacterial Agents ◽  
Antibacterial Activities ◽  
Clinical Isolates ◽  
Coagulase Negative Staphylococci ◽  
Vancomycin Resistant Enterococci ◽  
Resistant Strains ◽  
Vancomycin Resistant

ABSTRACT The antibacterial activity of DQ-113, formerly D61-1113, was compared with those of antibacterial agents currently available. MICs at which 90% of the isolates tested are inhibited (MIC90s) of DQ-113 against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus and methicillin-susceptible and -resistant coagulase-negative staphylococci were 0.03, 0.008, 0.03, and 0.06 μg/ml, respectively. Moreover, DQ-113 showed the most potent activity against ofloxacin-resistant and methicillin-resistant S. aureus, with a MIC90 of 0.25μg/ml. DQ-113 inhibited the growth of all strains of Streptococcus pneumoniae, including penicillin-resistant strains, and Streptococcus pyogenes at 0.06 μg/ml, and DQ-113 was more active than the other quinolones tested against Enterococcus faecalis and Enterococcus faecium with MIC90s of 0.25 and 2 μg/ml, respectively. Against vancomycin-resistant enterococci, DQ-113 showed the highest activity among the reference compounds, with a MIC range from 0.25 to 2 μg/ml. DQ-113 also showed a potent activity against Haemophilus influenzae, including ampicillin-resistant strains (MIC90, 0.015 μg/ml), and Moraxella catarrhalis (MIC90, 0.03 μg/ml). The activity of DQ-113 was roughly comparable to that of levofloxacin against all species of Enterobacteriaceae. The MICs of DQ-113 against ofloxacin-susceptible Pseudomonas aeruginosa ranged from 0.25 to 2 μg/ml, which were four times higher than those of ciprofloxacin. From these results, DQ-113 showed the most potent activity against gram-positive pathogens among antibacterial agents tested.

Sign in / Sign up

Export Citation Format

Share Document